Grifols SA ADR (GRFS)
Grifols, S.A. is a Barcelona-based healthcare company founded in 1909 that develops, produces, and markets plasma-derived medicines and related healthcare products. Its operations are organized across four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company’s portfolio includes hemoderivatives used in immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology, along with diagnostic testing systems, reagents, transfusion medicine, and clinical diagnostics services. Grifols also supplies biological products such as albumin, immunoglobulins, thrombin, and other plasma-derived materials for biopharma and diagnostic applications. In addition, it provides hospital solutions, medical devices, manufacturing and engineering services, and several support activities. The listed security is an ADR representing common stock of Grifols, S.A. on NASDAQ.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GRFS
|
$9.73
|
26.1% Upside
|
Undervalued
|
$10.87
|
40.7% Upside
|
Undervalued
|
Great
|
—
|
—
|
0.23
|
0.0%
|
July 28, 2026
|
13.9x
|
1.1x
|
0.8x
|
6.51 B
|
19.81 B
|
54.4%
|
61.4%
|
7.1
|
30.8%
|
181.4%
|
